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High-Risk Coronary Plaques*
Eugene Braunwald, MDP athologists have known for almost a halfcentury that disruption of coronary plaque isresponsible for coronary thrombosis (1), lead-
ing to acute coronary syndromes (ACS), including
sudden cardiac death (1,2). Clinicians, understand-
ably, want to detect these plaques before they
rupture so that they can undertake preventive mea-
sures. In their classic 1992 article on the pathogenesis
of coronary artery disease and ACS, Fuster et al. (3)
predicted, correctly, that “It may soon be possible to
detect fatty plaques in the vascular system by several
techniques, such as intravascular ultrasound (IVUS)
or noninvasive magnetic resonance imaging, ultrafast
computed tomography, spectroscopy, or radioisotope
imaging.”
Six years ago, I was invited to prepare an editorial
comment on an important paper on this subject
published in the Journal. Motoyama et al. (4) carried
out contrast-enhanced computed tomographic angi-
ography (CTA) in 1,059 patients with known or sus-
pected coronary artery disease (CAD) who were
followed for an average of 27 months (2,383 patient-
years). Only 15 (1.5%) of these patients experienced
an ACS, but 10 of these occurred among the 45 pa-
tients who showed positive coronary artery remod-
eling and exhibited plaques with low attenuation
(“soft plaques”) on CTA (4). This pivotal paper
opened the door to a noninvasive approach to the
detection of atherosclerotic plaques at high risk of
rupture, so-called “vulnerable plaques.” I suggested
that before widespread adoption of this interesting*Editorials published in the Journal of the American College of Cardiology
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order, as were further reﬁnements of the technology
and more potent therapies designed to prevent the
rupture of such plaques (5).
LESSONS LEARNED SINCE 2009
Not surprisingly, characterization of and efforts to
identify and treat such coronary plaques has
remained a subject of intense interest, and we have
learned much in the interim. Narula et al. (6) returned
to the pathology laboratory and characterized the
histopathological features of 295 coronary plaques
obtained postmortem from patients who died sud-
denly. They reported that thinning of the ﬁbrous cap
is a very important indicator of plaque vulnerability.
Although it is possible to make measurements of the
thickness of a cap overlying a lipid-ﬁlled necrotic core
in vivo using optimal coherence tomography or gray-
scale and radiofrequency IVUS (virtual histology),
these techniques obviously require coronary artery
catheterization. However, they also noted that
greater plaque burden and severe stenosis, both of
which can be assessed noninvasively by CTA, can be
helpful in determining the risk of plaque rupture.
Stone et al. (7) used IVUS to study 697 patients with
ACS who had undergone percutaneous coronary
intervention (PCI). The 3-year cumulative event rate
of recurrent ACS or cardiac death was 20.4%. Inter-
estingly, only about one-half of these events resulted
from recurrences at the site of the culprit lesion and
the other one-half to nonculprit lesions characterized
by thin cap ﬁbroatheroma, extensive plaque burden,
and small luminal area. As stated in the preceding
text, the 2 latter characteristics can be assessed non-
invasively by CTA.
During the past 6 years, CTA has certainly become
an important diagnostic tool in cardiology. In one
study, 34 of 368 patients who presented to an
emergency department with acute chest pain, but no
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348other signs of ischemia, had signiﬁcant coronary
stenosis on CTA, and 21 of these 34 had ACS.
Morphological characteristics predictive of ACS
included plaque length, plaque volume, and arterial
remodeling (8). Normal coronary arteries on CTA in
these patients essentially ruled out ACS (i.e., the
technique had a high negative predictive value). In
another analysis of CAD patients who underwent CTA
for diagnostic purposes and who were then followed
for an average of 3.6 years, Bittencourt et al. (9) re-
ported that patients with plaques that were extensive
and/or accompanied by severe obstruction had a
higher risk of cardiovascular death or myocardial
infarction than did patients whose plaques did not
have these features.
For many years, it has been accepted that athero-
sclerotic CAD is usually a generalized rather than a
focal disorder, and there is increased evidence of the
dynamic nature of the morphology of coronary arte-
rial lesion morphology. Serial studies, using largely
invasive techniques, have demonstrated that some
thin-cap, ﬁbrous, atheromatous lesions, the hallmark
of high-risk plaques, may increase in size and num-
ber, whereas other plaques may develop thicker caps
or even become frankly ﬁbrotic (10,11).
Important reﬁnements of noninvasive assessment
of plaques are ongoing. The uptake of 18F-2-
deoxyglucose (FDG) detected by positron emission
tomography (PET) occurs in metabolically active,
macrophage-rich regions, reﬂecting the inﬂammatory
changes in the plaque and neighboring arterial wall
that appear to be predictive of future vascular events
(12). The coupling of the morphology of plaques as
assessed by CTA to their metabolism ascertained by
FDG-PET, although complex and expensive, may in
the future permit more accurate noninvasive recog-
nition of high-risk plaques.
From a therapeutic perspective, although no new
anti-inﬂammatory drugs have been shown convinc-
ingly to reduce the risk of plaque rupture in the past
6 years, some such agents are now in phase III trials.
However, it is reassuring that high-dose statin ther-
apy, which is safe and now inexpensive, appears to
reduce atherosclerotic plaque volume and increase
ﬁbrous cap thickness. This action is likely to be the
result of resolution of inﬂammation secondary to
lowering of the plaque’s lipid content by the statin
(13). Although the issue has not been settled deﬁni-
tively, it does appear that in patients with ST-
segment elevation myocardial infarction who have
undergone PCI of their culprit artery, preventive PCI
of stenotic nonculprit arteries improves clinical
outcome. Whether this applies to other forms of ACS
is unclear (14).THE PRESENT STUDY
In this issue of the Journal, Motoyama et al. (15) now
have extended their earlier assessment of coronary
arteries by CTA to 3,158 patients and have followed
them over an average of 3.9 years, providing an
observation period of 12,316 patient-years, a morethan 5-fold greater experience than in their 2009
paper (4). During this period, 88 (2.8%) developed
an ACS. High-risk plaques were deﬁned as showing a
remodeling index (lesion diameter/reference diam-
eter) $1.1 and/or low plaque attenuation. They also
observed that when entered into a multivariable Cox
hazard analysis that included clinical variables, the
presence of high-risk plaques detected by CTA was an
independent predictor of subsequent ACS. Two CTAs
were carried out in 449 of their patients an average of
1 year apart. Both progression and stabilization of
coronary plaques were observed; the subsequent
risks of ACS were higher in patients in the former
group. Not surprisingly, ACS occurred 10 times more
frequently in patients with than in those without
high-risk plaques. Because the former were present in
only 9.3% of the patients, the actual number of pa-
tients developing ACS from these 2 groups was almost
identical: 45 in patients with and 43 in patients
without high-risk plaques, respectively. Therefore, if
a therapeutic intervention were carried out in only
the patients with high-risk plaques, the incidence of
the development or recurrence of ACS could, at best,
be reduced by one-half.
TAKE-HOME POINTS
There are several takeaways from this study:
1. Although patients with coronary artery plaques
having thin-walled ﬁbrous caps and large lipid-
ﬁlled necrotic cores are at the highest risk of
future ACS, cap thickness and plaque composition
cannot now be identiﬁed by any noninvasive
technique, including CTA.
2. Nevertheless, coronary anatomy can be ascer-
tained noninvasively and with reasonable accu-
racy using contrast-enhanced CTA in patients
with known or suspected CAD.
3. CTA may be useful clinically to rule out ACS in
patients with chest pain of unclear etiology pre-
senting to emergency departments.
4. In patients with chronic CAD, the number of
vessels with signiﬁcant obstruction on CTA cor-
relates directly with mortality. In symptom-
atic patients with suspected CAD, the negative
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349predictive value of a normal coronary CTA is high
and may be useful to rule out epicardial CAD.
5. Clinically apparent CAD usually involves more
than a single plaque; it is often a diffuse disease,
and it is dynamic, with several plaques in various
stages of formation, evolution, and regression at
any time.
6. CTA can detect high-risk plaques, characterized
by positive remodeling of the vessel and low
attenuation, and is often accompanied by signi-
ﬁcant stenosis of the artery in the region of
the plaque.
7. The detection of multiple high-risk plaques by
CTA identiﬁes patients at high risk of adverse
outcome and is an independent predictor of sub-
sequent ACS.
8. There is increasing interest in and emphasis on
the identiﬁcation of high-risk patients rather than
high-risk plaques (11,16).9. High-dose statin therapy reduces the number of
high-risk plaques and the patient’s risk of adverse
coronary events. New anti-inﬂammatory agents
are under active investigation. The use of pro-
longed antiplatelet therapy and the revasculari-
zation of nonculprit arteries with high-risk
plaques should be handled on a case-by-case
basis.
10. Combining metabolic with anatomic imaging,
such as the combination of PET with CTA, may
enhance the noninvasive characterization of
arterial plaques, thereby further improving risk
stratiﬁcation and management.
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